

Q3 2024/2025

NETWORK HIGHLIGHTS



NEUROLOGY NETWORK PRIORITISATION SURVEY

The Neurology Clinical Network conducted a national survey of Paediatricians and Allied Health Professionals aiming to identify gaps in service provision and support across the motu. Two surveys were developed and disseminated nationally, receiving 98 responses from multidisciplinary clinicians with wide regional representation. Results will be used to inform and prioritise future reference group activity.



GASTROENTEROLOGY NETWORK ADVOCACY CREATES IMPACT



New Zealand Funds First Oral Biologic for IBD

As a result of advocacy and collaboration of Gastroenterology CRG members with PHARMAC, access criteria for Upadacitinib (brand name Rinvoq) have been expanded to include inflammatory bowel disease (IBD). This marks the first time an oral biologic therapy for IBD has been publicly funded in Aotearoa. Taken as a once-daily tablet, Rinvoq offers an alternative to subcutaneous and intravenous treatments, easing the treatment burden for whānau and helping reduce demand on both primary and secondary healthcare services.

CHILD PROTECTION NETWORK LAUNCH QUARTERLY NEWSLETTER

The Child Protection Clinical Network has published its inaugural quarterly newsletter. This issue shares updates on the newly established Child Protection Clinical Governance Group (CGG), including cross-agency collaboration, national policy development, and opportunities for clinical input. The newsletter is part of the Network's ongoing commitment to strengthening child protection in Aotearoa. Stay tuned for future editions!



The Paediatric Society of New Zealand
Te Kāhui Mātai Arotamariki o Aotearoa